All In Biotech

Drug Trial Radar · NCT03861793

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)

Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

116

Actual

Start

Feb 26, 2019

Primary completion

Mar 1, 2023

Study completion Mar 1, 2023

Sponsor

Lead sponsor
Mural Oncology, IncIndustry
Sponsor type
Industry
First posted
Mar 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.

Conditions

  • Advanced Solid Tumors

Interventions

  • ALKS 4230Biological

    SC injection administered in the back of the arm or the abdomen

  • PembrolizumabBiological

    Administered as an intravenous (IV) infusion over 30 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs), and identify the RP2D of ALKS 4230 in Part ATime frame: From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months
  2. Number of subjects experiencing AEs that are both serious and drug-related in Part BTime frame: From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months
  3. Clinical Activity of combination treatment with ALKS 4230 and pembrolizumab in each Part B tumor type.Time frame: From time of therapy until the date of first documented tumor progression, assessed up to 24 months

Locations

48 sites in 6 countries. Site status is shown where the registry gives one.

  • Mural Oncology Investigational Site

    Los Angeles, California

  • Mural Oncology Investigational Site

    Los Angeles, California

  • Mural Oncology Investigational Site

    Washington D.C., District of Columbia

  • Mural Oncology Investigational Site

    Atlanta, Georgia

  • Mural Oncology Investigational Site

    Chicago, Illinois

  • Mural Oncology Investigational Site

    Bethesda, Maryland

  • Mural Oncology Investigational Site

    Detroit, Michigan

  • Mural Oncology Investigational Site

    Saint Paul, Minnesota

  • Mural Oncology Investigational Site

    Morristown, New Jersey

  • Mural Oncology Investigational Site

    Buffalo, New York

  • Mural Oncology Investigational Site

    Huntersville, North Carolina

  • Mural Oncology Investigational Site

    Cincinnati, Ohio

  • Mural Oncology Investigational Site

    Philadelphia, Pennsylvania

  • Mural Oncology Investigational Site

    Charleston, South Carolina

  • Mural Oncology Investigational Site

    Houston, Texas

  • Mural Oncology Investigational Site

    Salt Lake City, Utah

  • Mural Oncology Investigational Site

    Milwaukee, Wisconsin

  • Mural Oncology Investigational Site

    Edmonton, Alberta, Canada

  • Mural Oncology Investigational Site

    Hamilton, Ontario, Canada

  • Mural Oncology Investigational Sites

    Montreal, Quebec, Canada

  • Mural Oncology Investigational Site

    Montreal, Quebec, Canada

  • Mural Oncology Investigational Site

    Montreal, Quebec, Canada

  • Mural Oncology Investigational Site

    Québec, Quebec, Canada

  • Mural Oncology Investigational Site

    Rotterdam, Netherlands

  • Mural Oncology Investigational Site

    Utrecht, Netherlands

  • National Cancer Center

    Goyang, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Yonsei University Health System - Severance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, South Korea

  • Mural Oncology Investigational Site

    Badalona, Spain

  • Mural Oncology Investigational Site

    Córdoba, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

  • Mural Oncology Investigational Site

    Madrid, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.